UNSPSC 51111654: Raltitrexed

This classification denotes a thymidylate synthase inhibitor and folate antagonist with the molecular formula C21H22N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FCB9EGG971, chemically known as n-(5-(n-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-n-methylamino)-2-thenoyl)-l-glutamic acid but generally known as raltitrexed, which bears US NIH Compound Identifier 104758. European Medicines Agency schedules Raltitrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10244MIG.

UNSPSC 51111654 Raltitrexed is a Commodity code identifying a specific chemotherapy agent used in cancer treatment. State and local governments procure raltitrexed through pharmacy benefit managers, hospital formularies, and public health departments to support oncology services at public hospitals, correctional health systems, and safety-net clinics. The drug is typically acquired as part of broader pharmaceutical procurement contracts that bundle multiple cancer therapeutics, though it may also be sourced under specialty pharmaceutical or injectable-drug schedules through cooperative purchasing agreements with state pharmaceutical consortia or group purchasing organizations.

The source provided contains no recent state or local solicitations or contract opportunities under this code. Without access to current RFP, RFQ, IFB, or ITB postings, issuing-body mix, geographic concentration, and representative procurement activity cannot be characterized from available data.